This educational initiative is jointly provided by American Academy of CME, Inc. and E&S MedEd Group, Inc.
This activity is supported by an independent educational grant from Novo Nordisk Inc.
This review presents information on new and emerging injectable therapies in a question and case-based format. These new treatment options offer internal medicine physicians additional ways to improve glycemic control with the promise of greater tolerability.
This activity has been designed to meet the educational needs of general internal medicine physicians, internal medicine subspecialty physicians, and other healthcare professionals involved in the management of patients with type 2 diabetes mellitus (T2DM).
At the end of this CME activity, participants should be better able to:
Describe indications for starting basal insulin therapy in patients with T2DM
Use appropriate basal insulin in a physiologic manner and titrate therapy to achieve fasting plasma glucose goals
Acknowledge and address patient barriers to insulin therapy by explaining how new therapies have been designed to mitigate barriers
Intensify therapy in a patient-specific manner using new and emerging options, whether by premixed insulin or other prandial insulin or injectable therapies
Conflict Of Interest Disclosure Policy
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:
Lawrence Blonde, MD, FACP, MACE Director Ochsner Diabetes Clinical Research Unit Frank Riddick Diabetes Institute Department of Endocrinology Ochsner Medical Center New Orleans, LA
Dr. Blonde states that he serves on the Advisory Board for scientific information for AstraZeneca, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., and Sanofi. He has received Grant/Research Support to his institution from Lexicon Pharmaceuticals Inc., Novo Nordisk Inc., and Sanofi. He is on the Promotional Speaker’s Bureaus for AstraZeneca, Janssen Pharmaceuticals, Inc., and Novo Nordisk Inc.
Ayotunde O. Dokun, MD, PhD Associate Professor of Medicine and Endocrinology Chief Endocrine Services Regional One Health University of Tennessee Health Sciences Center Memphis, TN
Dr. Dokun states he has no relevant financial relationship to disclose.
Frank Lavernia, MD Founder North Broward Diabetes Center Coconut Creek, FL
Dr. Lavernia states he is on the Advisory Boards for marketing purposes and scientific information of Sanofi, Eli Lilly, and Janssen Pharmaceuticals. He is a Consultant for marketing purposes and is on the Promotional Speaker’s Bureau for Janssen Pharmaceuticals.
Planning Committee Disclosures
Laurie Ermentrout states that she has no relevant financial relationships to disclose.
John JD Juchniewicz, MCIS, CHCP, states that he has no relevant financial relationships to disclose.
Lisa Kehs states that she has no relevant financial relationships to disclose.
Kate Mann, PharmD, states her spouse was a part-time employee (now retired) of Otsuka Pharmaceutical Development and Commercialization, Inc.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Academy of CME, Inc., and E&S MedEd Group, Inc. American Academy of CME, Inc., is accredited by the ACCME to provide continuing medical education for physicians.
American Academy of CME, Inc., designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This activity may contain discussion of off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or E&S MedEd Group. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
There are no fees for participating in this activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.
To obtain a certificate, participants must receive a score of 70% or better on the post-test. The post-test can be accessed at the end of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.